Outcome of Treating Bladder Cancer in Sohag University Hospital
Sponsor
Sohag University (Other)
Overall Status
Completed
CT.gov ID
NCT05082818
Collaborator
(none)
168
1
7
24.1
Study Details
Study Description
Brief Summary
Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer
Study Design
Study Type:
Observational
Actual Enrollment
:
168 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Outcome of Treating Urinary Bladder Cancer in Sohag University Hospital Between 2016 to 2020
Actual Study Start Date
:
Oct 30, 2021
Actual Primary Completion Date
:
May 28, 2022
Actual Study Completion Date
:
May 30, 2022
Outcome Measures
Primary Outcome Measures
- Disease free survival [2 weeks after treatment to the time of relapse]
Time from the end of treatment to the date of first relapse
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- all stages and grades of urinary bladder cancer Any histological types of urinary bladder cancer
Exclusion Criteria:
- presence of other malignancies
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sohag University Hospital | Sohag | Egypt |
Sponsors and Collaborators
- Sohag University
Investigators
- Principal Investigator: Samah Refaat, Sohag University hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Samah Refat Ahmed,
resident of clinical oncology faculty of medicine Sohag University,
Sohag University
ClinicalTrials.gov Identifier:
NCT05082818
Other Study ID Numbers:
- Soh-Med-21-10-16
First Posted:
Oct 19, 2021
Last Update Posted:
Jun 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: